Effect of glycoprotein IIb/IIIa receptor blockade with abciximab on clinical and angiographic restenosis rate after the placement of coronary stents following acute myocardial infarction

Journal of the American College of Cardiology

Volumn 35, Issue 4, 2000, Pages 915-921

  Neumann, Franz Josef ^a   Kastrati, Adnan ^a   Schmitt, Claus ^a   Blasini, Rudolf ^a   Hadamitzky, Martin ^a   Mehilli, Julinda ^a   Gawaz, Meinrad ^a   Schleef, Michael ^a   Seyfarth, Melchior ^a   Dirschinger, Josef ^a   Schömig, Albert ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; TICLOPIDINE;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY INTIMA PROLIFERATION; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; CORONARY STENT; DRUG EFFECT; FEMALE; FOLLOW UP; HEART DEATH; HEART REINFARCTION; HUMAN; IMPLANTATION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTENOSIS; TRANSLUMINAL CORONARY ANGIOPLASTY; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; COHORT STUDIES; CORONARY ANGIOGRAPHY; FEMALE; HEPARIN; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RECURRENCE; STENTS; SURVIVAL RATE;

EID: 19244387281     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0735-1097(99)00635-X     Document Type: Article

References (26)

1. Lincoff A.M. Trials of platelet glycoprotein IIb/IIIa receptor antagonists during percutaneous coronary interventions. Am J Cardiol. 82:1998;36P-42P.
2. Neumann F.J., Schömig A. Glycoprotein IIb/IIIa receptor blockade with coronary stent placement. Semin Interv Cardiol. 3:1998;81-90.
3. Le Breton H., Plow E.F., Topol E.J. Role of platelets in restenosis after percutaneous coronary revascularization. J Am Coll Cardiol. 28:1996;1643-1651.
4. Willerson J.T., Eidt J.F., McNatt J., et al. Role of thromboxane and serotonin as mediators in the development of spontaneous alterations in coronary blood flow and neointimal proliferation in canine models with chronic coronary artery stenoses and endothelial injury. J Am Coll Cardiol. 7:1991;101B-110B.
5. Schwartz R.S., Holmes D.R., Topol E.J. The restenosis paradigm revisited an alternative proposal for cellular mechanisms . J Am Coll Cardiol. 20:1992;1284-1293.
6. A) polymorphism of platelet glycoprotein IIIa and risk of restenosis after coronary stent placement. Circulation. 99:1999;1005-1010.
7. 3) mediates platelet adhesion to the luminal aspect of endothelial cells. Implications for reperfusion in acute myocardial infarction. Circulation. 96:1997;1809-1818.
8. 3 integrin in the development of coronary artery restenosis after angioplasty. Proc Natl Acad Sci U S A. 94:1997;9308-9313.
9. 2-leukocyte integrin Mac-1 (CD11b/CD18) reduces intimal thickening after angioplasty or stent implantation in rabbits. Proc Natl Acad Sci U S A. 95:1998;10134-10139.
10. Lincoff A.M., Califf R.M., Moliterno D.J., et al. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. N Engl J Med. 341:1999;319-327.
11. Acute platelet inhibition with abciximab does not reduce in-stent restenosis (ERASER study). Circulation. 100:1999;799-806.
12. Cura F.A., L'Allier P.A., Sapp S., Lincoff A.M., Topol E.J. Comparison of the protection against restenosis afforded by stenting or abciximab. (abstr) J Am Coll Cardiol. 33:(Suppl A):1999;11A.
13. Willerson J.T., Yao S.K., McNatt J., et al. Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury. Proc Natl Acad Sci U S A. 88:1991;10624-10628.
14. Kastrati A., Schühlen H., Hausleiter J., et al. Restenosis after coronary stent placement and randomization to a four-week combined antiplatelet or anticoagulant therapy six-month angiographic follow-up of the intracoronary stenting and antithrombotic regimen (ISAR) trial . Circulation. 96:1997;462-467.
15. Neumann F.J., Blasini R., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation. 98:1998;2695-2701.
16. Schömig A., Neumann F.J., Walter H., et al. Coronary stent placement in patients with acute myocardial infarction comparison of clinical and angiographic outcome after randomization to antiplatelet or anticoagulant therapy . J Am Coll Cardiol. 29:1997;28-34.
17. Coller B.S. GPIIb/IIIa antagonists pathophysiologic and therapeutic insights from studies of c7E3 Fab . Thromb Haemost. 78:1997;730-735.
18. Simon D.I., Xu H., Ortlepp S., Rogers C., Rao N.K. 7E3 Monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol. 17:1997;528-535.
19. Fan S.T., Edgington T.S. Integrin regulation of leukocyte inflammatory functions. CD11b/CD18 enhancement of the tumor necrosis factor-alpha responses of monocytes. J Immunol. 150:1993;2972-2980.
20. 3) is implicated, in cooperation with P-selectin and platelet-activating factor, in the adhesion of monocytes to activated endothelial cells. Biochem J. 304:1994;537-542.
21. Brener S.J., Barr L.A., Burchenal J.E., et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. Circulation. 98:1998;734-741.
22. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 352:1998;87-92.
23. Serruys P.W., van Hout B., Bonnier H., et al. Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II). Lancet. 352:1998;673-681.
24. Kuntz R.E., Keaney K.M., Senerchia C., Baim D.S. A predictive method for estimating the late angiographic results of coronary intervention despite incomplete ascertainment. Circulation. 87:1993;815-830.
25. Suryapranata H., van't Hof A.W., Hoorntje J.C., de Boer M.J., Zijlstra F. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation. 97:1998;2502-2505.
26. Grines C.L., Cox D.A., Garcia E., et al. Stent PAMI primary endpoint results of a multicenter randomized trial of heparin coated stenting vs. primary PTCA for AMI . (abstr) Circulation. 98:(Suppl I):1998;I105.